📣Great NEW content featured on @TheLancet homepage - "Advancing women in science & health"

1/ Black #womeninmedicine - rising above invisibility by @onyi_eke @OnyekaOtugo @DrJessIsomMDMPH

thelancet.com/journals/lance… 2/ Advancing women in healthcare leadership: systematic review of multi-sector evidence on organisational interventions by @HelenaTeede & colleagues

thelancet.com/journals/eclin…

6 months to the day that I wrote our lead @TheLancet editorial on a mysterious new pneumonia-like outbreak drafting it in 3 hours instead of the usual 3 days. Colleagues gave input in 1 h instead of 24 h. 6 months for the world to change forever. #writing
thelancet.com/journals/lance… Writing a leader under those conditions is risky: what was the outbreak & would it spread? Are we making something of nothing? Should we go soft or hard on China’s response & transparency? What about this ‘lockdown’ of Wuhan, an intervention we thought of as draconian (ha ha).

What distinguishes this new #remdesivir trial in @TheLancet is that it was:

1. Peer-reviewed & professionally edited

2. Done by scientists w/o financial or other links to the drug's manufacturer, Gilead

3. Was "well conducted w/ high protocol adherence & no loss to followup"..

https://twitter.com/TheLancet/status/1255513005506215936

4. Accompanied by a commentary written by a leading statistical expert who calls for

5. "data sharing... allowing rapid curation of relevant datasets for individual patient data meta-analyses..."

and our "best way to obtain robust insights" on treatments for #COVID19 ...